Senté, a leader in medical-grade skincare innovation, announced the closing of a strategic partnership and equity financing. 

Senté entered a strategic partnership with an established firm alongside an equity investment from the firm and existing investors. 

This financing marks a pivotal moment for Senté as it continues to build on its strong foundation of science-driven innovation and deepen its presence across physician-dispensed channels and e-commerce platforms.

This milestone positions the company to accelerate growth and expand the reach of its patented Heparan Sulfate Analog (HSA) and Dermatan Sulfate and Chondroitin Sulfate (DECO) technologies, which are at the core of Senté’s clinically proven formulations and unique products.

As part of this next phase, the Senté Board of Directors has appointed co-founder Kleanthis G. Xanthopoulos, Ph.D., as Executive Chairman of the Board. 

A seasoned biotechnology entrepreneur, Dr. Xanthopoulos brings more than three decades of experience across the pharmaceutical and life sciences industries. He is currently the CEO and President of Senvera Therapeutics and serves on multiple private and public company boards.

Additionally, the Board has appointed Zubin Meshginpoosh as Chief Executive Officer and President.

Read Next

ELC Advances Skin Longevity and Regenerative Aesthetics